Sanofi Pasteur will invest $125 million for the rights to experimental vaccines using messenger RNA (mRNA) molecules for up to five infectious diseases developed by US firm Translate Bio . The infectious disease work isn’t Translate Bio’s main focus. John Shiver , the vaccines division of French pharmaceutical giant Sanofi , aims to harness the mRNA technology to create "next-generation vaccines", according to senior CureVac of R&D Sanofi Pasteur . Moderna Therapeutics , Translate Bio and BioNTech have secured billions to develop mRNA treatments, despite limited clinical data about the techniques' abilities.
Sanofi Pasteur will invest $125 million for the rights to experimental vaccines using messenger RNA (mRNA) molecules for up to five infectious diseases developed by US firm Translate Bio . John Shiver , the vaccines division of French pharmaceutical giant Sanofi , aims to harness the mRNA technology to create "next-generation vaccines", according to senior CureVac of R&D Sanofi Pasteur . Moderna Therapeutics , Translate Bio and BioNTech have secured billions to develop mRNA treatments, despite limited clinical data about the techniques' abilities.